Is there any data to support SLNB instead of ALND in patients with clinically N2-3 breast cancer after neoadjuvant chemotherapy?

Alliance Z-1071 cohort had 5% with cN2 and <1% fixed or matted and the current Alliance trial 011202 only allows cN1. ALND has never been shown to improve survival.